Abstract:Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in multiple cancers. However, durable antitumor responses have been observed in only a minority of patients, indicating the presence of other inhibitory mechanisms that act to restrain anticancer immunity. Therefore, new therapeutic strategies targeted against other immune suppressive mechanisms are needed to enhance anticancer immunity and maximize the clinical benefit of CIT in patients who are resistant to immune checkpoint inhibition. Preclinical and clinical studies have identified abnormalities in the tumor microenvironment (TME) that can negatively impact the efficacy of PD-1/PD-L1 blockade. Angiogenic factors such as vascular endothelial growth factor (VEGF) drive immunosuppression in the TME by inducing vascular abnormalities, suppressing antigen presentation and immune effector cells, or augmenting the immune suppressive activity of regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages. In turn, immunosuppressive cells can drive angiogenesis, thereby creating a vicious cycle of suppressed antitumor immunity. VEGF-mediated immune suppression in the TME and its negative impact on the efficacy of CIT provide a therapeutic rationale to combine PD-1/PD-L1 antibodies with anti-VEGF drugs in order to normalize the TME. A multitude of clinical trials have been initiated to evaluate combinations of a PD-1/PD-L1 antibody with an anti-VEGF in a variety of cancers. Recently, the positive results from five Phase III studies in non-small cell lung cancer (adenocarcinoma), renal cell carcinoma, and hepatocellular carcinoma have shown that combinations of PD-1/PD-L1 antibodies and anti-VEGF agents significantly improved clinical outcomes compared with respective standards of care. Such combinations have been approved by health authorities and are now standard treatment options for renal cell carcinoma, non-small cell lung cancer, and hepatocellular carcinoma. A plethora of other randomized studies of similar combinations are currently ongoing. Here, we discuss the principle mechanisms of VEGF-mediated immunosuppression studied in preclinical models or as part of translational clinical studies. We also discuss data from recently reported randomized clinical trials. Finally, we discuss how these concepts and approaches can be further incorporated into clinical practice to improve immunotherapy outcomes for patients with cancer.

Targeted treatment of anaerobic cancer. Patent evaluation of US2016279084 and US2017056350

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug

Glycolytic enzyme inhibitors in cancer treatment

Targeting glucose metabolism to develop anticancer treatments and therapeutic patents

Lactate dehydrogenase A inhibition by small molecular entities: steps in the right direction

Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer

Repurposing mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 for cancer therapy

Targeting the core program of metastasis with a novel drug combination

The Past and Future of Angiogenesis as a Target for Cancer Therapy and Prevention

Glycolysis inhibition for anticancer treatment

HER2-targeted Tumor immunotherapy

Antiangiogenic therapy: how far is it to upgrade?

Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism

Multitargeted anti-angiogenic agents and NSCLC: Clinical update and future directions

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities

The Potential of Antiangiogenic Therapy in Non–Small Cell Lung Cancer

Place des thérapeutiques biologiques ciblées

Angiogenesis as a Target for Tumor Treatment

Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives

Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy